Background: Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity.
Aim: To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC.
Methods: All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study. Severe TACE-related toxicity was defined as the occurrence of any adverse event grade ≥ 4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE. Factors predicting toxicity were identified using a logistic regression model. The robustness of the final model was confirmed using bootstrapping (500 replications).
Results: 124 patients were included, median age was 67 years and 90% were male; 22 patients (18%) experienced severe TACE-related toxicity. Factors that independently predicted severe TACE-related toxicity in multivariate analysis were total tumour size (OR, 1.15 cm(-1); 95%CI, 1.04-1.26; p=0.01), and high serum AST levels (OR, 1.10 per 10 IU/l; 95%CI, 1.01-1.21; p=0.04). The results were confirmed by bootstrapping.
Conclusions: Total tumour size and high serum AST levels were predictive factors of severe TACE-related toxicity in this hospital-based series of patients with unresectable HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dld.2013.12.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic implications of CK19 positivity in patients with early recurrent hepatocellular carcinoma after hepatic resection undergoing transarterial chemoembolization.
BMC Gastroenterol
October 2024
Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Gulou District, Nanjing, 210029, China.
Article Synopsis
- This study looked at how long patients with early recurring liver cancer (rHCC) survive after a specific treatment called TACE, and compared the results based on a protein called CK19.
- They analyzed 63 patients and found that those without CK19 (CK19-negative) lived longer than those with it (CK19-positive).
- The research suggested that CK19-positive patients may need extra treatments to help them live longer after TACE.
Effect and Safety of Prophylactic Parecoxib for Pain Control of Transarterial Chemoembolization in Liver Cancer: A Single-Center, Parallel-Group, Randomized Trial.
J Am Coll Radiol
January 2022
Department of Minimally Invasive Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address:
Objective: Pain is one of the most common side effects of transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma. The goal of this study is to compare the analgesic effect among celecoxib, parecoxib, and oxycodone in patients undergoing TACE.
Methods: This prospective study was a randomized, paralleled trial in which 213 patients were enrolled.
Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors.
Cardiovasc Intervent Radiol
August 2015
Department of Radiology, Seoul National University Hospital, 101, Daehangno, Jongno-gu, Seoul, 110-744, Korea.
Purpose: To assess the safety and effectiveness of transarterial chemoembolization (TACE) of patients who have hepatocellular carcinomas (HCCs) with central bile duct invasion.
Materials And Methods: The institutional review board approved this retrospective study and waived informed consent. Fifty-three patients, initially treated with TACE for HCCs with central bile duct invasion from January 1999 to September 2012, were included.
Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.
Dig Liver Dis
April 2014
University of Burgundy, 21079 Dijon, France; Department of Hepatogastroenterology, CHU (University Hospital), F-21079 Dijon, France. Electronic address:
Background: Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity.
Aim: To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC.
Methods: All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!